Ipsen (IPN) H2 2025 earnings summary

Executive summary

• Achieved double-digit sales growth of 10.9% year-over-year at constant exchange rates, with all three therapeutic areas—oncology, rare disease, and neuroscience—contributing to growth and significant profit expansion.

• Core operating margin improved to 35.2% of sales, with core operating income up 16.7% and free cash flow rising 29.2% to €1.0bn.

• Robust pipeline progress through internal R&D and external acquisitions, with five major regulatory and clinical milestones expected in 2026.

• Regulatory milestones included EU approval of CABOMETYX in neuroendocrine tumors and submission of tovorafenib for pediatric low-grade glioma.

• IFRS consolidated net profit increased by 28% to €445m, despite impairment losses.

Financial highlights

• Total sales reached €3.7bn, up 10.9% year-over-year at constant exchange rates.

• Core operating income rose 16.7% to €1.3bn, with a margin of 35.2%.

• Gross margin improved to 86.5% of sales, up 2.1 points from the previous year.

• Free cash flow reached €1.0bn, up 29.2% year-over-year.

• IFRS net profit increased by 28% to €445m, despite €350m in impairment losses.

Outlook and guidance

• 2026 guidance projects total sales growth above 13% at constant exchange rates and core operating margin above 35%.

• Confident in exceeding 7% annual sales growth and 32% margin by 2027.

• Guidance assumes continued Somatuline growth due to generic lanreotide production challenges and accelerated performance across the portfolio.

• Limited generic Somatuline supply anticipated in 2026, with potential generic entry in H2.